Skip to content
Kalpvruksh Markets
Offline Log in

MANKINDNSEOffline

MANKIND PHARMA · INE634S01028 · Mid Cap · #119
2,518.00−19.90 (−0.78%)last close · 05 Nov 2026
Prev close
2,537.90
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹91,937 cr
52-week range · to 05 Nov 20261,927.42,617.9

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

MANKIND is 4% below its 52-week high, above its 200-day average, ahead of Healthcare by 2.4 pts over 3 months — a Mid Cap company, #119 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 4% below its 52-week high
  • ahead of its industry by 2.4 pts over 3 months · rank 13 of 44 in Healthcare · +5.7% vs Nifty 500
  • traded value 1.5× usual · delivery 54% vs 56% usual
  • long unwinding today · IV 26%, 43rd pct of its year · expected move ±5.9% to expiry
  • FPI −0.1 pp · DII +0.2 pp · MF schemes in Sept 2026: 66 bought, 57 cut · no promoter pledge · quarter ended 2026-09-30
  • Sept 2026 quarter: profit +39% year on year · revenue +17%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹91,937 cr
Rank
#119
Cap band
Mid Cap
Nearest cut-off — Large / Mid
−13.61% from ₹1,06,417 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.4×
median 4,20,988
Delivered
1,72,385
Of volume
43%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+2.0%−3.7 pts—
1 month+0.7%−3.7 pts−3.1 pts
3 months+3.4%+5.7 pts+2.4 pts
6 months+6.6%+6.2 pts−3.8 pts
1 year+2.9%+5.7 pts—

Industry: Healthcare (Nifty 500 classification) · rank 13 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+5.4%
above
vs 50-day average
+5.3%
above
vs 200-day average
+8.6%
above
ATR (14)
3.5%
typical daily range
Volatility
42%
1 month, annualised
Beta
0.72
vs Nifty 500, 1 year
Traded value
1.5×
vs usual
Delivery
54%
usual 56%
From the 52-week high
−3.8%
place in range 86% (0 = at the low)

F&O

Where option open interest clusters

expiry 23 Nov 2026 · 18 days

Spot
2,518
Max pain
2,480
−1.5% from spot
Largest call OI (strike)
Largest put OI (strike)

Near expiry. Max pain is the strike at which option buyers’ total payout would be least; strikes with the most open interest are where positions cluster.

Volatility & expected move

ATM IV
26.5%
near expiry
IV 30
26.5%
IV rank
27
0–100 within its year
IV percentile
43
days in the year below today
Expected move to expiry
±148.12
±5.9% · one standard deviation
Range
2,370 – 2,666
Rollover
1%
futures OI in next expiries

Futures build-up, by day

all expiries' OI · today: long unwinding

SessionBuild-upFuture priceOI, all expiries
05 Nov 2026long unwinding−0.9%−3.3%
04 Nov 2026short covering+2.0%−1.2%
03 Nov 2026long build-up+0.4%+0.6%
02 Nov 2026short build-up−0.8%+1.2%
30 Oct 2026short covering+0.8%−2.7%
29 Oct 2026long unwinding−0.9%−2.9%
28 Oct 2026long unwinding−1.1%−0.4%
27 Oct 2026short covering+8.7%−6.1%
26 Oct 2026long build-up+4.6%+9.6%
23 Oct 2026long unwinding−3.0%−1.8%

From the exchanges’ F&O bhavcopies. A description of positions, not a forecast. Open interest across the market.

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters72.7%72.7%72.6%72.6%
FPI11.3%10.2% −1.19.4% −0.89.4% −0.1
Mutual funds9.3%10.4% +1.110.9% +0.511.3% +0.4
Other DII3.9%4.1% +0.14.5% +0.44.2% −0.3
Individuals1.5%1.4% −0.11.3% −0.11.3%
Others1.3%1.3%1.3%1.2%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
1,63,770
Individuals
1,56,273

Indian passive funds’ stake

2026-06-30

Of free float
0.89%
Of all shares
0.24%
Schemes
81
Days to unwind
1.3
at 100% of volume

10,05,801 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
229
81 index · 148 active
Bought more
101
Sold some
64
4 closing out
FundSharesChangeDid
Bank of India Flexi Cap Fund-Reg(G)Active+2,37,000+1580.0%bought
Aditya Birla SL Large Cap Fund-Reg(G)Active+9,60,243+317.7%bought
Aditya Birla SL Arbitrage Fund(G)Active+42,750+316.7%bought
WOC Large & Mid Cap Fund-Reg(G)Active−30,150−99.4%closing out
Mirae Asset Multi Asset Allocation Fund-Reg(G)Active−19,316−93.9%closing out
WOC Multi Cap Fund-Reg(G)Active−48,150−91.4%closing out

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 261949574611+1.0%₹10,846 cr
Aug 2619621731821+2.3%₹10,379 cr
Jul 2619619625416−0.0%₹10,356 cr
Jun 2619328633411+3.0%₹10,679 cr
May 261761259426−1.1%₹9,674 cr
Apr 26170775185+6.1%₹9,247 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 3 of 3 disclosures
0 selected
08 Feb 2024Sheetal AroraPromotersSell18,17,070₹383 cr4.81%Market Sale
08 Feb 2024Arjun JunejaPromoter GroupSell24,01,128₹506 cr2.04%Market Sale
08 Feb 2024Puja JunejaPromoter GroupSell22,71,336₹479 cr2.88%Market Sale

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Credit rating
    Mankind Pharma Limited has informed the Exchange about Credit Rating
    30 Oct 2026
  • Scheme / acquisition
    Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement
    26 Oct 2026
  • Board outcome
    Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    26 Oct 2026
  • Scheme / acquisition
    Mankind Pharma Limited has informed the Exchange about Acquisition
    16 Oct 2026
  • Board outcome
    Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 15, 2026.
    16 Oct 2026
  • Scheme / acquisition
    Mankind Pharma Limited has informed the Exchange about Acquisition
    14 Aug 2026

Latest shown; 8 in six months on all disclosures.

MANKIND: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹1Interim08 Aug 202508 Aug 2025

1 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.